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Abstract
Knowledge of uterine cervical epithelial biology and factors that influence its events may be
critical in understanding the process of cervical remodeling (CR). Here, we examine the
impact of exogenous vascular endothelial growth factor (VEGF) on uterine cervical epithelial
growth in mice (nonpregnant and pregnant) treated with VEGF agents (recombinant and
inhibitor) using a variety of morphological and molecular techniques. Exogenous VEGF
altered various uterine cervical epithelial cellular events, including marked induction of
growth, edema, increase in inter-epithelial paracellular space, and recruitment of immune
cells to the outer surface of epithelial cells (cervical lumen). We conclude that VEGF induces
multiple alterations in the uterine cervical epithelial tissues that may play a role in local
immune surveillance and uterine cervical growth during CR.
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Introductionmaintaining fluid balance via synthesis of hydrophilicDuring pregnancy, the uterine cervix undergoes a marked
growth, particularly in the last half of pregnancy
(Downing & Sherwood 1985, Hwang & Sherwood 1988),
where uterine cervical weight gain increases as much as
threefold in rats (Zarrow & Yochim 1961, Hwang et al.
1989). Notably, and of relevance to this study, prolifer-
ation of uterine cervical epithelial cells, in addition to
stromal cells, accounts for almost all the uterine cervical
growth that occurs during pregnancy (Buchanan et al.
1998). A detailed understanding of uterine cervical
epithelial biology has become essential because it is now
believed that they play important and broad range of roles
during uterine cervical remodeling (CR), which includehyaluronan, glycosaminoglycan, and aquaporins;
proliferation and differentiation; iii) regulation of
paracellular transport of solutes via tight junctions;
v) providing a protective barrier against invading micro-organisms, and mediating inflammatory and adaptive
immune responses; and v) acting as an ‘endocrine’
gland by synthesizing prostaglandins, chemokines, and
cytokines (e.g. interleukin-8) and steroid hormones
(Barclay et al. 1993, Pfundt et al. 1996, Mahendroo et al.
1999, Minjarez et al. 2000, Word et al. 2007). It is likely, as
some studies suggest that uterine cervical epithelial cells
may play the central role in CR.
To date, the key factors believed to modulate uterine
cervical growth are relaxin and estrogen (Kroc et al. 1959,
Cullen & Harkness 1960, Downing & Sherwood 1985,
Hwang & Sherwood 1988). Further, the uterine cervical
growth-stimulating effects of relaxin are believed to be
mediated by the estrogen/ERa genomic pathway, as mice
lacking ERa administered with relaxin do not display
uterine cervical growth compared to the wild-type group,
with an intact ERa (Yao et al. 2010). Because of the
redundant nature of most CR processes, uterine cervical
growth is also likely to be regulated by multiple factors,
either in a synergistic or complementary manner. It is
interesting to note that, like relaxin, vascular endothelial
growth factor (Vegf) expression is, in part, induced by
estrogen both in the uterus and in the uterine cervix, and
has a temporal, and to some extent, spatial relationship
with plasma estrogen levels (Mowa & Papka 2004,
Mowa et al. 2004, 2008, Lee & Sherwood 2005). Further
and intriguingly, relaxin stimulates robust expressions
of VEGF in the uterus and is known to exhibit
VEGF-like biological effects, including angiogenesis and
vascular permeability, in humans and rodents (see review
Dschietzig & Stangl (2003)). We do not know at this
point the functional relationship between relaxin and
VEGF in the uterine cervix.
We have previously characterized the presence
and profile of VEGF, the key architect of vascular events,
and its key receptors in the uterine cervix of rodents
(mice and rats) and delineated VEGF-related genes using
DNA microarray analysis (Mowa & Papka 2004, Mowa
et al. 2004, 2008, Newell et al. 2008, Nguyen et al. 2012).
The effects of VEGF are mediated by two tyrosine-
kinase receptors, namely VEGFR-1 (Flt1) and VEGFR-2
(Kdr/Flk1), which have different signaling properties and
are largely expressed by endothelial cells (Ferrara 2009).
Other cellular targets of VEGF, which express VEGF
receptors, include osteoblasts, mononuclear phagocytes,
hematopoietic cells, and some malignant cells (Chen
et al. 2004, Ferrara 2009). We recently noted using
scanning electron microscopy (SEM) that when ovari-
ectomized mice were treated with exogenous recombi-
nant VEGF administered intravaginally, it (VEGF)
induced pronounced folding of the uterine cervical
epithelial lining (Mowa et al. 2008). The increase in
uterine cervical epithelial folding was interpreted as
induction of uterine cervical epithelial proliferation,
implying that VEGF may also be a possible regulator
of uterine cervical growth.
In this study, we apply a more definitive technique,
i.e. bromodeoxyuridine (BrdU), to determine whether
VEGF induces uterine cervical epithelial proliferation.
We also examine other structural and molecular changes
induced by VEGF in uterine cervical epithelial cells and
the whole uterine cervical tissue in general, notably the
effect of VEGF on the recruitment of immune cells to the
uterine cervical epithelia and lumen.Materials and methods
Animals
Pregnant and nonpregnant (ovariectomized) C57BL6/
129SvEv mice (Mus musculus) sourced from Charles Rivers
were used in these studies (nZ3) either treated or under
different physiological conditions, as described in detail
below. Before tissue harvest, animals were administered
a lethal injection of sodium pentobarbital (Sleepaway,
Fort Dodge Laboratories, Inc., Burlingame, CA, USA)
and perfused intracardially immediately thereafter with
0.9% normal saline. Uterine cervical tissues were
carefully harvested under a stereomicroscope, to avoid
tissue contamination from vaginal or uterine tissues, and
the tissues were then processed and analyzed appro-
priately. Animals were housed under constant room
temperature (RT), with a 12 h light:12 h darkness cycle
and had free access to water and feed. All experiments were
performed in accordance with the Guide for the Care and
Use of Laboratory Animals of the local institution
(Appalachian State University) and the NIH guidelines
(NIH publication number 86-23), and efforts were made
to minimize both animal suffering and numbers of
animals used. Following treatments, tissues were analyzed
using various techniques, including morphological
techniques (basic immunohistochemistry (BrdU, SEM)
and gene expression (real-time PCR)), in order to elucidate
the effects of VEGF on various uterine cervical parameters
and events, namely uterine cervical epithelial structure
and proliferation.Treatments
Nonpregnant ovariectomized mice Before treat-
ments or tissue harvest, sexually mature mice w6-weeks
old weighing between 30 and 40 g were ovariectomized
(ovariectomyZremoval of ovaries). Prior to ovariectomy,
animals were anaesthetized with ketamine and xylazine
(43–129 mg ketamine and 8.6–26 mg xylazine/g) and then
rested for 7 days post-surgery to allow excretion of residual
ovarian sex steroid hormones. Significant reduction in
uterine size during tissue harvest indicated complete
excretion of residual ovarian hormones. Animals with
normal uterine size 7 days after ovariectomy were
eliminated from the study. Appropriate treatments were
administered by injecting either vehicle only (negative
control: 0.1 M PBS mixed with saturated (25%) pluronic
gel and kept in liquid form under ice) or VEGF agonist
(mouse recombinant VEGF 164 protein (Calbiochem, La
Jolla, CA, USA)) to nonpregnant ovariectomized mice
(nZ3/treatment group), following dosage, frequency, and
route optimization, as described below and previously
(Nguyen et al. 2012). Some mice were also treated with
VEGF inhibitor (PTK 787/ZK22584; generously provided
by Novartis Pharma AG):
Dose-dependent optimization Animals were
divided into two groups and treated with 50 ml of either:
i) increasing doses of mouse recombinant VEGF 164
protein (50 ng/mouse, 200 ng/mouse, or 400 ng/mouse)
or ii) vehicle only (0.1 M PBS). Both groups were initially
injected either i.p. and or intravaginally (via intraluminal
administration) (data not shown), once in the morning
(1000 h) and once in the evening (1600 h) respectively
daily for 4 days. Two hundred nanograms (200 ng) of
exogenous VEGF were found to be the optimal dosage
(Nguyen et al. 2012). After treatment, tissues were
harvested and split into ecto-cervix (uterine cervix portion
proximal to vagina) and endo-cervix (uterine cervix
portion proximal to uterus) by cutting the tissue
transversely midway. The tissues were then immediately
fixed in 2.5% glutaraldehyde (dissolved in 0.1 M PBS) for
SEM analysis (morphology). In later experiments of this
study, we eliminated chronic treatments (O24 h treat-
ments) for nonpregnant ovariectomized animals,
following results of a detailed optimization study of
exogenous VEGF treatment by another project in our
laboratory (Nguyen et al. 2012).
Time-dependent optimization Animalsweretreated
with a single injection (i.p.) of recombinant VEGF
(200 ng/mouse, i.p.) at time 0 h and tissues were harvested
inatime-dependentmanner, i.e.1 h45 min,2 h45 min,and
4 h 45 min post-VEGF treatment, as described earlier, and
fixedin10%formalinfor24 hbeforeprocessingthemfurther
for basic histological and immunohistochemical studies.
Cell proliferation and height Animals were treated
with a single injection (i.p.) of recombinant VEGF
(200 ng/mouse, i.p.) in a time-dependent manner, as
described under section Dose-dependent optimization
earlier. In addition, a day before and during VEGF
treatment, both groups were also treated with 50 ml (i.p.)
of BrdU, a uridine derivative and a structural analog of
thymidine, according to the manufacturer’s instruction
(Invitrogen). BrdU is incorporated into DNA during the
synthesis phase of the cell division as a substitute for
thymidine, thus can serve as a marker for proliferation.
Intestines from either group (VEGF- or vehicleonly-treated groups) were used as positive control tissues.
Animals were killed on the second day and tissues were
then harvested, fixed in 10% formalin, and analyzed using
immunohistochemistry and basic histology (H&E stain)
(Inverted Zeiss Light Microscope).
Determining optimal duration of VEGF treat-
ment This study was designed to determine the
optimal duration of VEGF treatment, i.e. single vs repeat
treatments. Animals were divided into two treatment
groups (nZ3) as follows: i) group 1 was given a single
injection of recombinant VEGF (200 ng dissolved in
25 ml of saturated pluronic gel and 0.1 M PBS, 25 ml per
injection, intravaginal (IV)) administered at timeZ0 h,
whereas ii) group 2 was given two consecutive injections
of recombinant VEGF (same dosage, solvent/media and
route as in group 1) administered at timeZ0 and 4 h
respectively. Both groups of animals were killed at 4 h
after-their last injection, tissues were then harvested
and frozen at K80 8C, and examined using quantitative
real-time PCR.Pregnant mice
Pregnant mice (days 11 and 17) w10- to 12-week old,
weighing between 60 and 80 g, were used, as described
below:
Baseline gene expression study (untreated)
Untreated timed pregnant animals (days 11 and 17 of
pregnancy, nZ3) were used in order to determine the
baseline gene expression pattern of VEGF and its receptors
(KDR and Flt1) in the uterine cervix. Animals were killed
at noon and tissues were then harvested and frozen
at K80 8C, processed, and examined using quantitative
real-time PCR.
Gene expression studies of animals treated with
VEGF agents (exogenousVEGF andVEGF inhibitor)
Pregnant animals (days 11 and 17) were treated with
either vehicle only or VEGF agents (exogenous VEGF and
inhibitor) via intraluminal IV, twice a day, morning
(1000 h) and afternoon (1600 h), as described here:
i) group 1 was given two consecutive injections of
recombinant VEGF (200 ng dissolved in 25 ml of saturated
pluronic gel and 0.1 M PBS, 25 ml/per injection, IV);
ii) group 2 was given two consecutive injections of VEGF
inhibitor (5 mg VEGF inhibitor/kg body weight, 50 ml/per
injection, i.p.; and iii) group 3 was given two consecutive
injections of vehicle (25 ml of saturated pluronic gel and
0.1 M PBS, 25 ml/per injection).Techniques
Determination of VEGF’s effects on uterine
cervical epithelialmorphology using SEM Experi-
ments were undertaken to visualize the effects of VEGF
on the morphology of uterine cervical epithelia of
ovariectomized mice. After fixing tissues overnight in
2.5% glutaraldehyde, the tissues were processed for SEM
analysis by first washing the tissues in the buffer, then
dehydrated in a graded series of ethanol, and critically
dried using a Polaron critical point drying apparatus
(Polaron Instruments, Inc., Doylestown, PA, USA).
Whole tissue samples were then mounted on aluminum
stubs sputter coated with gold and imaged using a Quanta
200 SEM (FEI Company, Hilsboro, OR, USA) at 20 kV.
Determination of VEGF’s effects on uterine cervi-
cal epithelial proliferation and height using BrdU
and basic histology This experiment was undertaken
to test our earlier speculation that VEGF causes cervical
epithelial cell growth based on increased cervical epithelial
folds, as revealed by SEM data (Mowa et al. 2008), using one
of the gold standard tests for cell proliferation, i.e. BrdU.
After treatment, described earlier (see Treatment, Cell
proliferation), animals were killed and tissues were
processed and sectioned using cryostat, and sections were
stained with anti-BrdU and processed further using
immunohistochemistry, according to the manufacturer’s
instructions (Invitrogen). Following staining, sections were
counterstained with hematoxylin, dehydrated in a series of
ethanol, and dipped in xylene before mounting. In another
of our earlier studies that revealed that VEGF induced
increased uterine cervical epithelial folds at a much lower
dosage of VEGF (Mowa et al. 2008), we used tissues from
that study to measure epithelial height of uterine cervix
using mounted sections viewed and analyzed under a
microscope (inverted Zeiss DIC light microscope). The
average height of uterine cervical epithelial cells (30 cells)
was obtained using the software MicroSuite Five (2009)
for each treatment group and plotted as a graph, to
determine the effects of treatments on epithelial height.
Determination of Vegf mRNA expression and its
receptors (Flt1 and KDR) in mice uterine cervix
Gene expression analysis was performed using real-time
PCR to determine the effects of VEGF agents (recombinantVEGF164 protein and VEGF inhibitor) on the mRNA
expression of Vegf and its receptors, KDR and Flt1, in the
uterine cervix of pregnant mice. Gene expression analysis
was performed in three steps, as described below:
i) Tissue processing, mRNA isolation, and quanti-
fication: following treatments, animals were killed and
transcardially perfused with normal saline (0.9% sodium
chloride). The cervices were harvested immediately,
snap-frozen, and either processed or stored at K80 8C
until processing. Total RNA was isolated from individual
uterine cervices using the RNeasy Mini Kit (Qiagen) and
then the quality and quantity of each sample were
estimated using Nanodrop Spectrophotometer (Nano-
drop, Wilmington, DE, USA). Aliquots of total RNA were
diluted in RNase-free deionized (DI) water and either
stored at K80 8C or processed for reverse transcriptase
PCR, as described below.
ii) Reverse transcriptase PCR (RT-PCR): total RNA from
the uterine cervical tissues was reverse transcribed and
amplified in an Eppendorf Master Cycler (Hamburg,
Germany) using reagents from Applied Biosystems. For
generation of cDNA, 1.0 mg of previously isolated total
RNA was placed in a total volume of 9.5 ml per sample with
RNase-free water, as determined by Nanodrop Spectro-
photometer, described earlier. The RNA was incubated for
5 min at 65 8C and cooled to RT for 10 min, then 9.5 ml of
reverse transcriptase master mix was added to each tube,
which comprised reverse transcriptase buffer (2 ml per tube
of RNA; Applied Biosystems); MgCl2 (2 ml per tube of RNA;
Applied Biosystems), dNTP (2 ml per tube of RNA; Applied
Biosystems), RNase inhibitor (0.5 ml per tube of RNA;
Applied Biosystems), RNAse-free water (2 ml per tube of
RNA; Applied Biosystems), and random hexamers (1 ml per
tube of RNA; Applied Biosystems). Lastly, 1.0 ml of MuLV
reverse transcriptase (Applied Biosystems) was added to
each tube. One tube received no reverse transcriptase
enzyme to serve as a nontemplate control for DNA
contamination. The thermocycler was programmed to
run at 25 8C for 10 min, 42 8C for 2 h, 95 8C for 5 min, and
4 8C. The generated total cDNA was then used to evaluate
mRNA levels of the genes of interest, as described below.
iii) Real-time PCR: relative expressions of the genes of
interest (Vegf, Kdr, and Flt1) were evaluated using real-time
PCR. Only fold changes O2 were accepted as significant.
TaqMan Gene Expression Assays (Applied Biosystems),
which are pre-designed and pre-optimized gene-specific
probe sets, were used and DNA amplification was
performed using the Applied Biosystems real-time PCR
machine (ABI 7300 HT) with the GeneAmp 7300 HT
sequence detection system software (Perkin-Elmer Corp.)
A
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C DThe real-time PCRs were set up in wells of 96-well plates in
a volume of 25 ml per well. The reaction components
included 1000 ng (5.0 ml) of synthesized cDNA, 12.5 ml 2X
Taqman Universal PCR Master Mix, 1.25 ml 20X Assays-on-
Demand Gene Mix (e.g. VEGF), and 6.25 ml real-time
PCR-grade RNAse-free water. The program was set as
follows: an initial step of 50 8C for 2 min and 95 8C for
10 min and then 40 cycles of 95 8C for 15 s and 60 8C for
60 s. The relative amount was calculated from the
threshold cycles with the instrument’s software (SDS 2.0),
according to the manufacturer’s instructions. Relative
expression levels of the target genes were normalized to
the geometric mean of the endogenous control gene,Gusb.20 µm 20 µm
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Figure 1
VEGF alters the ultrastructure of uterine cervical epithelial cell, as revealed
by SEM images. Ovariectomized mice treated with VEGF recombinant
protein 164 (B, D and F) (200 ng/mouse, single treatment of either i.p. or
intravaginal) induces folds (blue arrows) and a general swelling in uterine
cervical epithelial sheets compared with ovariectomized control group
treated with vehicle only, i.e. PBS (A, C and E), where cell types (red and
white stars) and borders (short white arrows) are more distinct than in
VEGF-treated mice (*). Red circle in A and B are sites on the ecto-side of the
uterine cervix from which images C, D, E and F were taken (nZ3).
Magnification: A and BZ!100; C and DZ!5000; E and FZ!10 000.Results
VEGF alters the ultrastructure of uterine cervical epithelial
cells and induces transepithelial recruitment of WBC
SEM analysis of ecto- and endo-uterine cervical tissues
from ovariectomized animals treated with exogenous
VEGF revealed pronounced alterations in the ultra-
structure of uterine cervical epithelial cell compared with
the control groups (Figs 1, 2 and 3). Specifically, in
ecto- cervices, VEGF induced folds, edema-like appear-
ance, and less pronounced inter-epithelial cellular
borders), compared with the control group (Fig. 1). In
endo-cervices, the most striking features of VEGF on
uterine cervical epithelial cells were the dose-dependent
recruitment and transepithelial migrations of white blood
cells (WBC) into the uterine cervical lumen, which was not
observed in ecto-cervix. Furthermore, as with ecto-cervix,
the inter-epithelial borders in endo-cervix were also less
prominent due perhaps to edema (Fig. 2), and increase in
inter-epithelial paracellular space was obvious even at a
much lower dosage, a feature that was attenuated by VEGF
inhibitor (Fig. 3). At the dose of 400 ng/mouse of
recombinant VEGF, there was a much greater infiltration
and migration of WBC into the uterine cervical lumen
of endo-cervices. However, at this dosage, the uterine
cervical epithelial layer began to peel-off in both the
ecto- and endo-cervices (data not shown).VEGF induces proliferation of uterine cervical
epithelial cells
Treatment of ovariectomized mice with VEGF induced
pronounced proliferation of uterine cervical epithelial
cells in a time-dependent manner, and the peak growth
occurred at 4 h 45 min post-VEGF treatment, with theleast at 1 h 45 min (Fig. 4) and 6 h (data not shown) post-
VEGF treatment respectively. Further, VEGF treatment at a
much lower dosage of 20 ng/mouse (w!5 lower) almost
doubled epithelial height compared with control group,
i.e. 12 mm (VEGF) vs. 7.5 mm (control) (Fig. 5).VEGF alters gene expression of VEGF and its receptors
in uterine cervices of pregnant mice
Uterine cervix mRNA levels of VEGF and its receptors were
found to be unchanged between gestational days 11
through 16 but increased sharply by day 17 (P!0.05)
(Fig. 6). Treatment of pregnant animals with VEGF at days
11 but not 17 of pregnancy tended to upregulate VEGF and
its two receptors, KDR and Flt1, whereas blockage of
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Figure 2
VEGF induces recruitment of WBC on the outer surface of uterine cervical
epithelial cell or lumen, as revealed by SEM images: ovariectomized mice
treated with VEGF recombinant protein 164 (B, D and F) (200 ng/mouse,
single treatment of either i.p. or intravaginal) causes WBC (blue arrows)
recruitment from uterine cervical tissue into the uterine cervical lumen and
a change in cellular shape compared with ovariectomized control group
treated with vehicle only, i.e. PBS (A, C and E). Cells in control group (red
stars) have distinct borders (red arrows) compared with VEGF-treated mice
(*). Red circle in A and B are sites on the endo-side of the uterine cervix
from which images C, D, E and F were taken (nZ3). Magnification: A and
BZ!100; C and DZ!5000; E and FZ!10 000.endogenous VEGF at day 11 but not 17 of pregnancy using
VEGF inhibitor downregulated expression of VEGF and its
receptors, KDR and Flt1 (Fig. 7).Discussion
Uterine cervical epithelial cells are now believed to play a
central role in uterine CR by regulating multiple func-
tions, cited earlier in the introduction (Barclay et al. 1993,
Pfundt et al. 1996, Mahendroo et al. 1999, Minjarez et al.
2000, Word et al. 2007). We have previously shown that
exogenous VEGF administered to ovariectomized mice
induces folding of the uterine cervical epithelia layer using
SEM and interpreted these data to mean that VEGFinduces proliferation of uterine cervical epithelial cells
(Mowa et al. 2008). This study builds on these earlier
observations and was primarily aimed at investigating the
effects of VEGF on uterine cervical epithelial cell prolifer-
ation using a more definitive technique, namely BrdU.
The key findings of this study are that VEGF promotes
i) proliferation of uterine cervical epithelial cells in a
temporal- and dose-dependent manner; ii) WBC
transepithelial recruitment from the tissue into the
uterine cervical lumen; and iii) folding and edema in
uterine cervical epithelial cells. Collectively, these find-
ings suggest that VEGF may influence uterine CR, in part,
by influencing a variety of uterine cervical epithelial cell
events, such as uterine cervical epithelial cell proliferation,
transepithelial cell recruitment, and local immune sur-
veillance. The observed effects of VEGF on epithelial
events may have physiological significance that may
impact CR (Fig. 8).
In the second half of pregnancy, the uterine cervix of
rats rapidly proliferates, i.e. by as much as threefold, an
effect that is largely attributed to the actions of relaxin and
estrogen (Downing & Sherwood 1985, Hwang & Sherwood
1988). The effects of relaxin on uterine cervical growth
(stromal and epithelial cells), which accounts for 40–50%
of uterine cervical growth, is believed to be mediated by
estrogen, as mice lacking ERa and administered with
relaxin have low uterine cervical and vaginal wet weight
compared with wild type (Cooke, LoTurco and Sherwood,
unpublished). Also the temporal and, to some extent,
spatial expression patterns of these two molecules and
their respective receptors coincides (Kroc et al. 1959,
Cullen & Harkness 1960). Estrogen is also known to
promote uterine cervical growth independent of relaxin
(Kroc et al. 1959). Because relaxin receptors are only
localized in the uterine cervical stromal, but not epithelial
cells, it is believed that relaxin influences epithelial growth
via a paracrine mechanism, which has also been described
in the uterus and other tissues (Yao et al. 2010). However,
the exact mechanisms of relaxin’s proliferative effects are
not fully understood, as exogenous estrogen down-
regulates relaxin receptors in ovariectomized rat (Kumar
and Sherwood, unpublished observations).
Here, we show a novel regulatory factor that promotes
uterine cervical epithelial growth, i.e. VEGF, using
nonpregnant ovariectomized mice, as revealed by BrdU.
This study builds on SEM data from our previous study
that showed increased cervical epithelial folds following
administration of exogenous VEGF and was interpreted as
an indication of increased epithelial growth (Mowa et al.
2008). These (present) data are also consistent with our
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Figure 3
Effects of VEGF (low dose, 40 ng/mouse) on uterine cervical epithelial folds
and inter-epithelial gap space: (A and D) VEGF recombinant protein
induces epithelial folds of uterine cervical tissue and inter-epithelial spaces
(*) respectively in ovariectomized mice compared with control (B), treated
only with PBS. Figures C and F show that blocking the action of VEGF via
administration of its inhibitor reverses the effects of VEGF and changes the
normal appearance of the cells (low magnification, !149) compared with
ovariectomized control group (E) administered with PBS only (high
magnification, !9000) (nZ3).earlier genome-wide gene expression data that revealed
sharp decreases in expression of genes associated with cell
proliferation (K8.11-fold), cell motility (K7.66), and cell
adhesion molecule activity (K1.96) (Mowa et al. 2008). At
this point, the precise mechanism of VEGF’s proliferative
effects on uterine cervical epithelial growth and its
relationship with the other two regulatory factors known
to promote growth of this cell type are unclear. It is,
however, intriguing to note that there are some striking
similarities and overlap between VEGF and the other two
regulatory factors (relaxin and estrogen) in some of their1) Post VEGF
injection:
2) Tissue type: Cervix (target tissues)
1h 45 min 2h 45 min
20 µm
80 µm 400 µm
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Figure 4
Effect of VEGF on uterine cervical epithelial cell proliferation: VEGF
recombinant protein 164 (200 ng/mouse, single treatment of either i.p. or
intravaginal) induces proliferation of uterine cervical epithelial cells in
ovariectomized mice, shown here using BrdU immunostaining, a marker
for proliferation (red arrows point to brown staining). The maximum
proliferative effects of VEGF were observed at about 5 h (C and F) and byphysiological effects and mechanisms (Bani & Bigazzi
1984, St-Louis & Massicotte 1985, Tischer et al. 1991,
Bani-Sacchi et al. 1995, Unemori et al. 1999, Seibold et al.
2002, Dschietzig & Stangl 2003).
We here show another interesting and novel phenom-
enon of VEGF in the uterine cervix, i.e. induction of
transepithelial migration of immune cells into uterine
cervical lumen. The exact mechanism/s mediating this
phenomenon is also not yet clear. However, it is equally
intriguing that this novel phenomenon also strikingly
resembles a well-established action of VEGF in another cellIntestine (positive control)
4h 45 min
80 µm
20 µm 20 µm
C
F G
E
E
E
the sixth (image not shown) post-VEGF treatment, BrdU immunostaining
significantly diminished. Small intestines, which have a robust prolifer-
ation, were used as positive control tissue (G) (nZ3). (A, B, D and E) Black
arrows point to epithelial cells, both nondividing and those undergoing
proliferation.
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Figure 5
Effects of VEGF treatment on uterine cervical epithelial height in
ovariectomized mice. Animals were either treated with recombinant VEGF
(40 ng/mouse daily for 2 days) or with vehicle only (0.1 M PBS). Histological
sections of uterine cervical epithelial tissues of these animals were then
stained with H&E and the heights of the cells were measured at !60 and
plotted as a graph, shown here. The average height of the cells in animals
treated with VEGF were greater than control (nZ20, *P!0.05).
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Figure 6
mRNAexpressionpatternofVEGFreceptors,Flt1 (A)andKDR(B),andVEGF(C)
in uterine cervix of pregnant mice (days 11–17), as revealed by real-time PCR.
mRNA levels of all the three genes increased over the course of pregnancy.
nZ3; *P!0.05 for days 11 vs 17.type that is structurally similar to uterine cervical
epithelia, namely vascular endothelial cells (Ferrara &
Davis-Smyth 1997). In these cells (endothelial), VEGF
induces immune extravasation from blood vessels into the
tissue matrix by promoting vascular permeability or
increasing inter-endothelial paracellular spaces by a factor
of 50 000-fold more than histamine (Van Bruggen et al.
1999). This vascular leakage, working together with
established chemoattractant gradients, leads to migration
of immune cells from blood vessels to the sites of injury.
Our understanding of mechanisms underlying
transepithelial migration of immune cells across classical
or traditional epithelial cells is only a decade old and is
largely derived from observations of pathogen interaction
with intestinal epithelial cells (reviewed by Berkes et al.
(2003)). Data from these studies have shown that invasion
of epithelial cells by bacteria induces an inflammatory
response through expression and secretion of a charac-
teristic pattern of cytokines by epithelial cells (McCormick
et al. 1998, Caamano & Hunter 2002). These inflammatory
responses are mediated by a variety of signaling pathways,
including NFKB, PKC, and MAPK (Bird et al. 1997, Monick
et al. 1999, Savkovic et al. 2002). The mobilized cytokines
will then recruit a variety of effector cells, including
neutrophils, lymphocytes, eosinophils, and monocytes, to
the basolateral border of the invaded epithelial cells.
Neutrophils will then migrate to the apical end of the
epithelia and lumen, close or proximal to the invading
bacteria, via the inter-epithelial cellular matrix. This
second wave of migration is made possible by anotherset of cytokine gradients, notably IL8, secreted on the
basolateral border of epithelial cells (Madara et al. 1993).
The uterine cervical epithelium is composed of squamous
cells on the ecto- or external portion of the uterine cervix
and cuboidal cells on the internal side or endo-cervix. CR
is likely to be more pronounced on the endo-cervix as it is
more exposed during effacement. The significance of the
differences in reaction to VEGF treatment observed
between ecto- and endo-cervix in immune cell recruitment,
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Figure 7
The effects of VEGF agents (agonist and inhibitor) on mRNA expression of
VEGF receptors, Flt1 (A) and KDR (B), and on VEGF (C) in uterine cervix of
pregnant mice (days 11 and 17), as revealed by real-time PCR. Generally,
exogenous VEGF tended to upregulate mRNA levels of all the three genes
on day 11 of pregnancy, in contrast to VEGF inhibitor, compared with the
control group. nZ3; P!0.05 for days marked with asterisk (*). However, no
difference was noted in late pregnancy (day 17).reported in this study, is for now unclear. We do know that
there may be some differences in the barrier function of the
two epithelial types. For instance, endo-cervical columnar
cells appear to have tighter junctions than the superficial
layers of the ecto-cervix (Blaskewicz et al. 2011). Further
studies are required to tease out these differences.
We are currently investigating the exact mechanisms
of VEGF in transcervical epithelial recruitment and
migration of immune cells and its significance in
local surveillance, and whether IL8, mediates these effects.We recently demonstrated that exogenous VEGF adminis-
tered vaginally (intraluminally) induces an inflammatory
response by upregulating mRNA expression of classical
pro-inflammatory factors, including TNFa, IL6, and COX
II, implying that VEGF likely plays a role in the
inflammatory response of uterine cervical epithelial cells
during pathogenic invasions (Nguyen et al. 2012). These
observations are also consistent with our earlier DNA
microarray studies that observed a 4.70-fold decrease in
genes associated with immune response and decrease in
expression of an array of chemokine, interleukins, and LPS
binding protein, when VEGF actions were blocked in the
cervix of pregnant rats by VEGF inhibitor (Mowa et al.
2008). As for the potential role of VEGF in local
surveillance, it is interesting to note that nitric oxide,
the key mediator of VEGF action, has been shown to have
multiple regulatory functions in intestinal epithelia,
including barrier function, antimicrobial activity
(De Groote & Fang 1995, Alican & Kubes 1996, Fang 1997),
and promotion of chloride secretion (Rolfe & Milla 1999).
VEGF was first described as a potent vascular
permeability factor (Senger et al. 1986). As stated earlier,
compared with other endogenous potent vascular
permeability factors, such as histamine, VEGF is 50 000
times stronger (Van Bruggen et al. 1999) and its role
in tissue edema induction is well established, including in
tissue types such as uterine, brain, and nasal tissues
(Van Bruggen et al. 1999). For instance, antagonism of
VEGF action in brain or stroke injury-induced edema
significantly reduces swelling and hyper-permeability of
brain microvasculature (Roberts & Palade 1995, Van
Bruggen et al. 1999, Dafni et al. 2002). In nasal polyps,
expression of VEGF and KDR is localized in plasma cells
and appears to be involved in signal transduction (Ito et al.
1995). Other conditions that may induce expression of
VEGF in the brain, which in turn induces cerebrovascular
permeability, include hypoxia and ischemic brain injuries
(Van Bruggen et al. 1999). The exact role of edema in CR,
particularly in epithelial cells, is not completely under-
stood. One possible role is that it may provide turgor
pressure, as is the case in plants and erection, i.e. the fluid
pressure provides mechanical support to the otherwise
softening tissues, allowing the uterine cervix to maintain
its barrier properties, while at the same time remodeling
and preparing itself for the final process of fetal passage or
birth. Thus, VEGF likely plays two seemingly opposing
roles, namely enhancing CR, while maintaining the
uterine cervical barrier properties via edema formation.
Factors and mechanisms that underlie the regulation
of VEGF and its receptors in the uterine cervix are not
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Aproposedmodel for VEGF’s effects onuterine cervical epithelial growth (7)
and immune cell recruitment (2–6) into the uterine cervical lumen. These
twoevents likely play a role inCRand local immune surveillance respectively.
Exogenous VEGF (1) induces inflammatory response by epithelial cells,
which may lead to establishment of a pro-inflammatory gradient (2) that
attracts immune cells (3–6) to the site of stimulation or irritation.completely known. We do know sensory-derived neuro-
peptides and inflammation-inducing factors can upregu-
late levels of VEGF in the uterine cervix, as well exogenous
estrogen and hypoxia simulation (Mowa & Papka 2004,
Mowa et al. 2004, Nguyen et al. 2012, T Ohashi, S Jesmin,
D Anumba and CN Mowa unpublished). Here, we show
that mRNA expression of Vegf and that of its receptors
increase over the course of pregnancy, with a sharp rise in
late pregnancy. These findings are consistent with our
earlier studies that characterized the profile of VEGF
mRNA and protein expression and its receptors, and
angiogenesis in the uterine cervix of pregnant rats over
the course of pregnancy (Mowa et al. 2004). These two
findings, together with other studies, show a temporal
and/or causative relationship between VEGF and uterine
cervical events, such as growth, angiogenesis (microvas-
cular remodeling), hypoxia, plasma estrogen levels,
inflammation, and neuropeptide expression. Here, we
also show that exogenous VEGF administered to mice
during early, but not late, pregnancy upregulates mRNA
expression of endogenous VEGF and its receptors, which
were attenuated by VEGF inhibitor. This suggests a
possible existence of a positive VEGF autoregulatory
mechanism during early pregnancy, which may magnify
VEGF’s biological effects and, importantly, possibly CR as
well. The current observation is similar to findings of an
earlier study that showed that low levels of VEGF
significantly upregulated the expression of VEGF receptors
(Flt1 and KDR), as well as enhanced adult neuralprogenitor cell differentiation into neurons in the rat.
However, unlike our study, high doses downregulated
expression of VEGF receptors as well as neurogenesis and
they did not examine exogenous VEGF’s effect on the
levels of endogenous VEGF (Meng et al. 2006). Future
studies will examine the influence of VEGF on the overall
growth of the uterine cervix during pregnancy.
In conclusion, this study has shown that VEGF
induces multiple alterations in the uterine cervical tissues
of mice, notably increased epithelia growth, folding,
edema, and increase in inter-epithelial paracellular spaces
leading to recruitment of WBC into the uterine cervix.
Collectively, these findings suggest that VEGF plays a role
in local surveillance during CR by inducing an inflam-
matory response and uterine cervical growth (epithelial
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